An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
NCT ID: NCT01543503
Last Updated: 2016-02-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1225 participants
OBSERVATIONAL
2012-02-29
2015-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Non-Interventional Study in Patients With Rheumatoid Arthritis Who Are Treated With RoActemra/Actemra (Tocilizumab)
NCT01893255
An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients
NCT01615419
An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)
NCT01565122
An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis
NCT01741688
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
NCT01394276
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of rheumatoid arthritis
* Non-respondent or intolerant to non-biologic disease-modifying anti-rheumatic drug (DMARD) therapy
* Patient has been prescribed a first biologic therapy up to 6 weeks prior to the inclusion visit, irrespective of the treatment prescribed
Exclusion Criteria
* Patients who are receiving or have received experimental DMARDs as part of a clinical trial studying RA treatment in the last 12 months
* Patients whose first biologic is rituximab, abatacept or anakinra.
* Patients who have received any biologic therapy for more than 6 weeks prior to the inclusion visit
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Catamarca Capital, , Argentina
Mendoza, , Argentina
Mendoza, , Argentina
Rosario, , Argentina
Aalst, , Belgium
Assebroek, , Belgium
Aye, , Belgium
Brussels, , Belgium
Brussels, , Belgium
Edegem, , Belgium
Genk, , Belgium
Ghent, , Belgium
Godinne, , Belgium
Heusy, , Belgium
Liège, , Belgium
Ostend, , Belgium
Verviers, , Belgium
Westmalle, , Belgium
Barranquilla, , Colombia
Bogotá, , Colombia
Bucaramanga, , Colombia
Medellín, , Colombia
Cuenca, , Ecuador
Esmeraldas, , Ecuador
Guayaquil, , Ecuador
Portoviejo, , Ecuador
Quito, , Ecuador
Quito, , Ecuador
Quito, , Ecuador
Aachen, , Germany
Bad Aibling, , Germany
Bad Neuenahr-Ahrweiler, , Germany
Bayreuth, , Germany
Berlin, , Germany
Cologne, , Germany
Dresden, , Germany
Erfurt, , Germany
Erlangen, , Germany
Fulda, , Germany
Hamburg, , Germany
Hamburg, , Germany
Heidelberg, , Germany
Herne, , Germany
Ludwigsfelde, , Germany
München, , Germany
München, , Germany
Passau, , Germany
Rostock, , Germany
Stuttgart, , Germany
Traunstein, , Germany
Wuppertal, , Germany
Athens, , Greece
Athens, , Greece
Pátrai, , Greece
Thessaloniki, , Greece
Thessaloniki, , Greece
Guatemala City, , Guatemala
Coppito, Abruzzo, Italy
Pescara, Abruzzo, Italy
Brindisi, Apulia, Italy
Martina Franca, Apulia, Italy
San Cesario di Lecce, Apulia, Italy
Reggio Calabria, Calabria, Italy
Avellino, Campania, Italy
Napoli, Campania, Italy
Napoli, Campania, Italy
Salerno, Campania, Italy
Udine, Friuli Venezia Giulia, Italy
Rome, Lazio, Italy
Rome, Lazio, Italy
Arenzano, Liguria, Italy
Brescia, Lombardy, Italy
Legnano, Lombardy, Italy
Milan, Lombardy, Italy
Milan, Lombardy, Italy
Agnone, Molise, Italy
Turin, Piedmont, Italy
Turin, Piedmont, Italy
Catania, Sicily, Italy
Jesi Ancona, The Marches, Italy
Prato, Tuscany, Italy
Perugia, Umbria, Italy
Guadalajara, , Mexico
Guadalajara, , Mexico
Guadalajara, , Mexico
Mexicali, , Mexico
Mexico Ctiy, , Mexico
Panama City, , Panama
Almada, , Portugal
Amadora, , Portugal
Lisbon, , Portugal
Lisbon, , Portugal
Porto, , Portugal
Porto, , Portugal
Vila Nova de Gaia, , Portugal
Fuenlabrada, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
San Sebastián de los Reyes, Madrid, Spain
Aarau, , Switzerland
Basel, , Switzerland
Chur, , Switzerland
Sankt Gallen, , Switzerland
Donetsk, , Ukraine
Kharkiv, , Ukraine
Kmelnytskyy, , Ukraine
Kyiv, , Ukraine
Kyiv, , Ukraine
Kyiv, , Ukraine
Odesa, , Ukraine
Uzhhorod, , Ukraine
Zaporizhzhya, , Ukraine
Barnsley, , United Kingdom
Basildon, , United Kingdom
Basingstoke, , United Kingdom
Brighton, , United Kingdom
Cannock, , United Kingdom
Cardiff, , United Kingdom
Chertsey, , United Kingdom
Crawley, , United Kingdom
Darlington, , United Kingdom
Enfield, , United Kingdom
Grimsby, , United Kingdom
Guildford, , United Kingdom
Ipswich, , United Kingdom
Kettering, , United Kingdom
Lancaster, , United Kingdom
Leeds, , United Kingdom
Llandudno, , United Kingdom
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Luton, , United Kingdom
Maidstone, , United Kingdom
Margate, , United Kingdom
Metropolitan Borough of Wirral, , United Kingdom
North Shields, , United Kingdom
Oswestry, , United Kingdom
Plymouth, , United Kingdom
Portsmouth, , United Kingdom
Reading, , United Kingdom
Rhyl, , United Kingdom
Romford, , United Kingdom
Sheffield, , United Kingdom
Stockport, , United Kingdom
Sunderland, , United Kingdom
Swindon, , United Kingdom
Torquay, , United Kingdom
Warrington, , United Kingdom
Wolverhampton, , United Kingdom
Wrightington, , United Kingdom
Montevideo, , Uruguay
Montevideo, , Uruguay
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Choy EH, Bernasconi C, Aassi M, Molina JF, Epis OM. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study. Arthritis Care Res (Hoboken). 2017 Oct;69(10):1484-1494. doi: 10.1002/acr.23303. Epub 2017 Sep 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MA27950
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.